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Summary
Objective: To investigate the in vitro effects of dehydroepiandrosterone (DHEA) on human osteoarthritic chondrocytes.
Design: Chondrocytes isolated from human osteoarthritic knee cartilage were three-dimensionally cultured in alginate beads, except for cell
proliferation experiment. Cells were treated with DHEA in the presence or absence of IL-1β. The effects on chondrocytes were analyzed
using a 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay (for chondrocyte
proliferation), a dimethylmethylene blue (DMB) assay (for glycosaminoglycan (GAG) synthesis), and an indole assay (for DNA amount).
Gene expressions of type I and II collagen, metalloproteinase-1 and -3 (MMP-1 and -3), and tissue inhibitor of metalloproteinase-1 (TIMP-1)
as well as the IL-1β-induced gene expressions of MMP-1 and -3 were analyzed by reverse transcription-polymerase chain reaction
(RT-PCR). The protein synthesis of MMP-1 and -3 and TIMP-1 was determined by Western blotting.
Results: The treatment of chondrocytes with DHEA did not affect chondrocyte proliferation or GAG synthesis up to 100 µM of concentration.
The gene expression of type II collagen increased in a dose-dependent manner, while that of type I decreased. DHEA suppressed the
expression of MMP-1 significantly at concentrations exceeding 50 µM. The gene expression of MMP-3 was also suppressed, but this was
without statistical significance. The expression of TIMP-1 was significantly increased by DHEA at concentrations exceeding 10 µM. The
effects of DHEA on the gene expressions of MMP-1 and -3 were more prominent in the presence of IL-1β, in which DHEA suppressed not
only MMP-1, but also MMP-3 at the lower concentrations, 10 and 50 µM, respectively. Western blotting results were in agreement with
RT-PCR, which indicates that DHEA acts at the gene transcription level.
Conclusions: Our study demonstrates that DHEA has no toxic effect on chondrocytes up to 100 µM of concentration and has an ability to
modulate the imbalance between MMPs and TIMP-1 during OA at the transcription level, which suggest that it has a protective role against
articular cartilage loss.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is a degenerative joint disease charac-
terized by progressive loss of articular cartilage, sub-
chondral bone remodeling, spur formation, and synovial
inflammation. OA is believed to be a consequence of
mechanical and biochemical events that result in an imbal-
ance between the synthesis and degradation of articular
cartilage matrix1. The target of therapy is becoming more
focused on the specific steps of OA pathophysiology rather
than on the broad inhibition of inflammation or the relief of
pain. In OA, the principal cause of joint morbidity results
from the degradation of the articular extracellular matrix
(ECM) of articular cartilage, which results from the acti-
vation of various proteases and proinflammatory cytokines.
The proinflammatory cytokines are believed to play a
pivotal role in the initiation and development of the OA; of
those, IL-1β and TNF-α appear prominent2,3. IL-1β and
TNF-α appear to be first produced by the synovial mem-
brane and then to diffuse into articular cartilage through the
synovial fluid. They then activate chondrocytes, which in
turn produce many catabolic factors.
Il-1β has been implicated in the transcriptional upregu-
lation of various MMPs, including MMP-14,5and MMP-36,7.
The MMPs are an enzyme superfamily of at least 21
members, which can be classified into subgroups of colla-
genases (MMP-1, -8, -13), stromelysins (MMP-3, -10, -11),
gelatinases (MMP-2, -9), and as membrane-type 1 (MMP-
14)8. The collagenases are distinguished from the other
MMPs by their ability to cleave triple helical regions of
cartilage type II collagen. Stromelysin-1 (MMP-3) degrades
several ECM molecules, including aggrecan and type II
collagen9–11. In addition, MMP-3 is known to be essential
for the full activation of proMMP-112.
This study was funded by Korea Ministry of Health and Welfare
Grant 02-PJ11-PG6-EV11-0002 and HMP-00-CH-08-0007.
*Address correspondence and reprint requests to: Myung
Chul Lee. Tel: 82-2-760-3212; Fax: 82-2-764-2718; E-mail:
leemc@snu.ac.kr
Received 17 October 2002; revision accepted 8 April 2003.
International
Cartilage
Repair
Society
585
OsteoArthritis and Cartilage (2003) 11, 585–594
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/S1063-4584(03)00094-3
The activity of MMPs is controlled by the tissue inhibitor
of metalloproteinase (TIMP), a glycoprotein that inhibits all
MMPs at a stoichiometry of 1:1, by forming high-affinity
complexes13. Imbalance between MMPs and TIMPs is well
known to be of importance in the progression of OA14,15.
Dehydroepiandrosterone (DHEA) is a 19-carbon steroid
hormone, classified as an adrenal androgen. DHEA is
synthesized from pregnenolone (derived from cholesterol)
and is rapidly sulfated to its ester form, DHEA-S, the
predominant form in circulating plasma16. Because of its
decline with age, DHEA is well known as an ‘antidote for
aging’, and a number of studies are currently being per-
formed on its role in atherosclerosis17, cancer18, diabetes,
obesity19, and aging20, as well as inflammatory arthritis,
such as rheumatoid arthritis21–23. In rheumatoid arthritis
patients, the serum level of DHEA has been found to be
lower than in healthy controls24, while the cause remains
unknown. In addition, the exogenous administration of
DHEA was found to offer protection against the develop-
ment of collagen-induced arthritis in an animal model25.
While a previous study has reported on the effect of
DHEA on collagenase and gelatinase production26, nothing
is known about the effects of DHEA on OA, as far as we are
aware. In the present study, we investigated the in vitro
effects of DHEA on osteoarthritic chondrocytes, including
their proliferation, GAG synthesis, and expressions of
MMP-1, -3, and TIMP-1. In addition, we assessed the
effects of DHEA on the gene expressions of MMP-1 and -3
in the presence of exogenous IL-1β.
Materials and methods
ISOLATION AND EXPANSION OF HUMAN OA CHONDROCYTES
Human OA cartilage was obtained from the femoral
condyles of OA patients undergoing knee joint replacement
surgery. Cartilage was washed in calcium- and
magnesium-free phosphate buffered saline (DPBS) and
finely minced. Chondrocytes were released from articular
cartilage after being digested for 1 h with 0.2% pronase
(Sigma, St. Louis, MO, USA), followed by digestion for 3 h
with 0.2% collagenase (Sigma) at 37°C in high-glucose
Dulbecco’s modified Eagle medium (DMEM; Life Technolo-
gies, Rockville, MD, USA) containing antibiotic–antimycotic
solution (100 U/ml penicillin, 100 µg/ml streptomycin, and
0.25 µg/ml amphotericin B; Life Technologies). After remov-
ing undigested cartilage using a 70 µm nylon sieve, the
chondrocytes were collected by centrifugation, washed
twice, resuspended in DMEM supplemented with 10% fetal
bovine serum (FBS; Life Technologies), 25 µg/ml L-ascorbic
acid (Sigma) and antibiotics (hereafter called growth
medium), and finally plated in 100-mm tissue culture dish
for expansion at 37°C in a humidified atmosphere of 5%
CO2 for 7 days.
CULTURE OF CHONDROCYTES IN ALGINATE BEADS
After 7 days in monolayer culture, chondrocytes were
washed twice and harvested with trypsin–EDTA (0.25%
trypsin, 0.53 mM EDTA; Life Technologies). They were then
centrifuged, washed twice, and suspended in a 1.2%
solution of sterile alginate in 0.15 M NaCl at a density of
4×106 per ml. The cell suspension was slowly expressed
through a 22-gauge needle, dropped into a 102 mM CaCl2
solution, and allowed to polymerize for 10 min. Beads were
washed twice with 0.15 M NaCl, twice in DMEM, and were
then transferred to six-well plate and cultured for 5 days
before experiments in growth medium at 37°C in a humidi-
fied atmosphere of 5% CO2.
TREATMENT OF DHEA AND RECOMBINANT HUMAN IL-1β
In a series of experiments on cell proliferation and GAG
synthesis, chondrocytes in monolayer culture for prolifer-
ation assay or chondrocytes in alginate beads for GAG
assay were incubated in growth medium with 0, 10, 50, or
100 µM of DHEA (Sigma) for 7 days. In another series of
experiments on the gene expressions of MMP-1, -3, and
TIMP-1, alginate beads were incubated in growth medium
with 0, 10, 50, or 100 µM of DHEA for 3 days. In addition,
to examine the effects of DHEA on IL-1β-induced gene
expressions of MMP-1 and -3, beads were incubated in
growth medium with 0, 10, 50, or 100 µM of DHEA in
the presence of 1000 pg/ml of recombinant human IL-1β
(IL-1β; Calbiochem, CA, USA) for 3 days. For Western blot
analysis, beads were incubated in growth medium with 0,
10, and 100 µM of DHEA for 3 days. The growth medium
and IL-1β were changed every other day.
CELL PROLIFERATION ASSAY
Chondrocytes proliferation assay was performed
using the 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS)
method using a commercially available kit (CellTiter 96
Aqueous; Promega, Madison, WI, USA) according to the
manufacturer’s instruction. Briefly, after 7 days in mono-
layer culture, chondrocytes were washed twice and har-
vested with trypsin–EDTA (0.25% trypsin, 0.53 mM EDTA;
Life Technologies). The chondrocytes were centrifuged,
washed twice, and resuspended in growth medium at a
density of 5×103 cells per well in a 96 multiwell plate. At
designated times (1, 3, and 7 days), 100 µl of phenazine
methosulfate (PMS) solution was added to 2.0 ml of MTS
solution, immediately before the mixture was added to the
cells. The cells were incubated for 90 min at 37°C in a
humidified atmosphere of 5% CO2. Plates were read on
a microplate spectrophotometer (Versamax; Molecular
Devices Corp., Sunnyvale, CA, USA) at 492 nm.
GLYCOSAMINOGLYCAN AND DNA AMOUNT ASSAY
For glycosaminoglycan (GAG) assay, the media were
harvested every 3 days and pooled for each 7-day period.
At each specified time (1, 3, and 7 days), the beads were
dissolved as described previously and centrifuged at 300×g
for 10 min at 4°C, obtaining two fractions: a supernatant
containing macromolecules from the further-removed com-
partment; and a pellet containing cells with their cell-
associated matrix (CM). The media, supernatant, and pellet
were digested for 12 h at 55°C in papain buffer (200 µg/ml
papain in 50 mM EDTA, 5 mM L-cystein, pH 3.0). GAG
amount was quantified using dimethylmethylene blue
(DMB) assay27. The metachromatic reaction of GAG with
DMB was monitored using a spectrophotometer, and the
ratio A540:A595 was used to determine the amount of GAG
present, using chondroitin sulfate C (Sigma) as a standard.
The amount of DNA in each sample collected by centrifug-
ing of the papain-treated pellet was determined using
indole assay28. Total amount of GAG was normalized vs
the total amount of DNA.
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REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
Total RNA was extracted using a RNA extraction kit
(Qiagen, Germany). The cDNA was synthesized using
0.5 µg of RNA and random hexamers in a commercially
available kit (First Strand cDNA Synthesis kit; MBI
Fermentas, Lithuania) according to the manufacturer’s
recommendations. The resulting cDNA was then amplified
by PCR using another commercially available kit
(Accupower; Bioneer, South Korea) in 20 µl using three
thermocycler temperatures (Perkin–Elmer, Norwalk, CT,
USA). Glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) reverse transcriptase-polymerase chain reaction
(RT-PCR) products were used for normalization. All
reactions were determined to be in a linear range of
amplification within cyclic numbers 14 to 30. Primers used
for human GAPDH, type I and II collagen, MMP-1 and -3,
and TIMP-1 are itemized in Table I. A single cycle consisted
of 30 s denaturation at 94°C, 30 s annealing at 60°C, and
30 s extension at 72°C. A 10 µl sample of the reaction
mixture was electrophoresed on 1.5% agarose gel contain-
ing ethidium bromide to evaluate the amplification and
determine the size of the generated fragments. A 100 bp
DNA ladder (Bioneer) was used as a standard size
marker. A densitometric computer program (TINA; Raytest
Isotopenmeßgerate, Germany) was used to analyze the
scan of the RT-PCR agarose gel after photographic
documentation. The program measured the relative mean
density of the bands of the PCR products corrected with
respect to the background.
WESTERN BLOT ANALYSIS
Beads incubated with 0, 10, or 100 µM of DHEA for
3 days were dissolved as previously described, and cell
pellets were immediately lysed in lysis buffer containing
50 mM Tris (pH 8.0), 150 mM NaCl, 1 mM Na3VO4,
100 µg/ml phenylmethylsulfonyl fluoride (PMSF), 1 µg/ml
aprotinin, and 1% Triton X-100 (all from Sigma), and
centrifuged at 16 000×g for 10 min. Total protein in the
supernatants was determined by Bio-Rad protein assay
(Bio-Rad, Hercules, CA, USA) using bovine serum albumin
(BSA) as a standard. The syntheses of MMP-1, -3, and
TIMP-1 were assayed in 50 µg samples of protein extracts
using mouse anti-human MMP-1 Ab-1 (CloneX2A; Neo-
markers, Fremont, CA, USA), mouse anti-human MMP-3
Ab-2 (Clone SL-1 IID4; Neomarkers), and mouse anti-
human TIMP-1 Ab-2 (102D1; Neomarkers) as primary
antibodies, and sheep anti-mouse IgG conjugated with
horseradish peroxidase (HRP; Amersham Biosciences,
UK) as a secondary antibody, and luminol as a chemi-
luminescent HRP substrate.
STATISTICAL ANALYSIS
All experiments were performed in triplicate. Results
were expressed as means±standard deviation of three
experiments. Statistical comparisons were made using
Kruskal–Wallis test to examine differences between
individual data points. Statistical significance was set at
P<0.05.
Results
EFFECTS OF DHEA ON CELL PROLIFERATION AND GAG SYNTHESIS
The effect of DHEA on cell proliferation was examined at
DHEA concentrations of 0, 10, 50, 100 µM after 1, 3, and 7
days of culture (Fig. 1). Chondrocytes at every concen-
tration proliferated actively and achieved more than five
population doublings by day 7. No significant differences
were observed between cells treated with different DHEA
concentrations at different times (P>0.05). These results
demonstrate that DHEA treatment did not affect chondro-
cyte proliferation at any of these concentrations.
The effect of DHEA on GAG synthesis was examined by
DMB assay at DHEA concentrations of 0, 10, 50, 100 µM
after 1, 3, and 7 days of culture [Fig. 2(A–D)]. Total amount
of GAG synthesis increased with time at all concentrations,
but no statistical significance was found [P>0.05; Fig. 2(A)].
While GAG in further-removed matrix (FRM) did not seem
to change apparently, GAG in media, and especially in CM,
tended to increase with time [Fig. 2(B–D)]. However, no
Table I
Polymerase chain reaction primer sequences
Gene Sequences Genebank accession number
GAPDH BC014085
Sense 5′-ATTGTTGCCATCAATGACCC-3′
Antisense 5′-AGTAGAGGCAGGGATGATGTT-3′
Type I collagen S64596
Sense 5′-CTCGAGGTGGACACCACCCT-3′
Antisense 5′-CAGCTGCATGGCCACATCGG-3′
Type II collagen NM_033150
Sense 5′-GAATTCGGTGTGGACATAGG-3′
Antisense 5′-TACAGAGGTGTTTGACACAG-3′
MMP-1 NM_002421
Sense 5′-ATTCTACTGATATCGGGGCTTTGA-3′
Antisense 5′-ATGTCCTTGGGGTATCCGTGTAG-3′
MMP-3 AF405705
Sense 5′-CTCACAGACCTGACTCGGTT-3′
Antisense 5′-CACGCCTGAAGGAAGAGATG-3′
TIMP-1 BC007097
Sense 5′-AATTCCGACCTCGTCATCAGG-3′
Antisense 5′-ACTGGAAGCCCTTTTCAGAGC-3′
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statistical significances were found between different con-
centrations or between different time points during the
culture period. These results suggest that DHEA, at least,
does not impair the GAG production by chondrocytes.
EFFECTS OF DHEA ON THE GENE EXPRESSIONS OF TYPE I AND II
COLLAGEN, MMP-1, -3, AND TIMP-1
Triplicate PCRs produced nearly identical results. The
figures presented are representatives of the results
obtained. PCR products of GAPDH were detected in all
RNA preparations, which confirmed the uniformity of the
RNA preparations. The mRNA expression of type I collagen
was significantly suppressed by DHEA treatment at 50 and
100 µM (P<0.05), while that of type II collagen was signifi-
cantly enhanced by DHEA treatment at the same concen-
trations (P<0.05) (Fig. 3). DHEA appeared to reduce the
mRNA expression of type I in a dose-dependent manner.
Type I collagen expression was maximally inhibited at a
concentration of 100 µM and was reduced to 28% of that of
the non-DHEA-treated control. Similarly, type II collagen
expression was maximally enhanced at a DHEA concen-
tration of 100 µM; up to 146% of that of the non-DHEA-
treated control.
The effects of DHEA on the gene expressions of MMP-1,
-3, and TIMP-1 were investigated with increasing concen-
trations of DHEA (Fig. 4). The gene expression of MMP-1
was significantly suppressed at concentrations of 50 and
100 µM (P<0.05), while the gene expressions of MMP-3
showed a similar suppressed pattern that was not of
statistical significance (P>0.05). DHEA also significantly
increased the gene expression of TIMP-1 at the lower
concentration of 10 µM. The dose-dependent effect of
DHEA was observed most prominently for the decreased
gene expression of MMP-1, compared with those of MMP-3
and TIMP-1. The gene expression of MMP-1 was maxi-
mally suppressed to 48% of that of the non-DHEA-treated
control at 100 µM, and that of MMP-3 was slightly sup-
pressed to 82–93% of the control, regardless of DHEA
concentrations. DHEA also enhanced the gene expression
of TIMP-1 up to 120% of the control, although maximum
gene expression occurred at 50 µM.
EFFECTS OF DHEA ON THE GENE EXPRESSIONS OF MMP-1 AND -3
IN THE PRESENCE OF IL-1β
IL-1β has been shown to induce the gene expression and
the protein synthesis of metalloproteinases (MMPs), while
it reduces only the synthesis of TIMP without affecting its
gene expression29. After investigating the effects of DHEA
on the mRNA expressions of MMP-1, -3, and TIMP-1, we
studied whether DHEA treatment modulates IL-1β-induced
gene expressions of MMP-1, and MMP-3. First, we deter-
mined the IL-1β concentration by culturing chondrocytes
with increasing concentrations of IL-1β (0, 10, 100, and
1000 pg/ml) and measured the mRNA expressions of
MMP-1 and -3 by RT-PCR as described previously. IL-1β
was found to significantly induce the mRNA expressions of
MMP-1 and -3 in a dose-dependent manner, and the
maximal expressions of MMP-1 and -3 were 470 and 310%
of that of the non-treated control, respectively, at 1000 pg/
ml. Considering this result, we decided to use IL-1β at
1000 pg/ml.
Chondrocytes were cultured with 0, 10, 50, or 100 µM of
DHEA and 1000 pg/ml of IL-1β for 3 days. DHEA signifi-
cantly decreased IL-1β-induced gene expression of MMP-1
from the lowest concentration of 10 µM, dose dependently,
to 74 and 53% of the non-treated control level at 10 and
50 µM, respectively (Fig. 5). The suppressive effect of
DHEA plateaued above 50 µM of DHEA. DHEA at 50 µM
also significantly decreased the IL-1β-induced gene ex-
pression of MMP-3, which was in contrast with the result
obtained without IL-1β (P<0.05). The MMP-3 gene expres-
sion was maximally suppressed to 73% of that of the
control at a DHEA concentration of 100 µM (P<0.05).
Fig. 1. The effect of DHEA on chondrocyte proliferation as deter-
mined by the MTS assay. Five thousand chondrocytes were
initially plated in each well of a 96-well plate and treated with DHEA
at 0, 10, 50, and 100 µM. On days 1, 3, and 7, the number of viable
cells was measured by MTS assay. Experiments were performed
in triplicate. Chondrocytes actively proliferated during culture, but
no significant differences in viable cell numbers were observed at
the different concentrations.
Fig. 2. The effect of DHEA on GAG synthesis as determined by the
DMB assay. (A) Total GAG, (B) GAG in media, (C) GAG in FRM,
(D) GAG in CM. Chondrocytes in alginate beads were treated with
DHEA at 0, 10, 50, and 100 µM. On days 1, 3, and 7, the alginate
beads were dissolved, and the total amount of GAG was deter-
mined by measuring the amount in media, supernatants, and
pellets, and by summing them. (A) Total amount of GAG increased
over the culture period of 7 days, but no significant difference was
observed between the different concentrations or during the cul-
ture period. (B–D) In media, there was only small amount of GAG
release from beads and it tended to increase over time. GAG
amount in CM increased most prominently over the culture period
in all beads at all concentrations, while that in FRM, it increased
slightly.
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EFFECTS OF DHEA ON THE PROTEIN SYNTHESIS OF MMP-1, -3,
AND TIMP-1
To determine whether the suppression of MMP-1 and -3
mRNA levels and the enhancement of TIMP-1 mRNA levels
are accompanied by an increase in protein synthesis, we
assayed the production of mature MMP-1, -3, and TIMP-1
in the lysates of chondrocytes by Western blot analysis
(Fig. 6). As was the mRNA expression, the protein level of
MMP-1 was dose dependently reduced by treatment with
DHEA, while that of MMP-3 was unchanged on increasing
the concentration of DHEA. The translational level of
mature TIMP-1 was significantly increased on increasing
the concentration of DHEA, and this dose-dependent
increase appeared more pronounced by Western blot
analysis. Thus, it was found that the transcriptional effects
of DHEA are associated with the translational activities for
MMP-1, -3, and TIMP-1.
Discussion
This is the first study to demonstrate the in vitro effects of
DHEA on osteoarthritic chondrocytes. We used alginate
beads as a three-dimensional scaffold to culture chondro-
cytes, as they have been demonstrated to be compatible
with chondrocytes30,31. In the present study, we analyzed
the effects of DHEA on chondrocyte proliferation, GAG
synthesis, the gene expressions, and protein syntheses of
type I and II collagen, catabolic enzymes such as MMP-1,
-3, and inhibitor of MMPs, such as TIMP-1, which are
known to play important roles in the progression of OA.
Furthermore, the effects of DHEA on IL-1β-induced gene
expressions were also investigated. We found that DHEA
has an ability to modulate the imbalance between MMPs
and TIMP-1 during OA at the transcription level, which
suggests that DHEA has a protective role against articular
Fig. 3. The effects of DHEA on the gene expressions of type I and II collagen measured by RT-PCR. Chondrocytes in alginate beads were
treated with DHEA at 0, 10, 50, and 100 µM for 3 days. Experiments were performed in triplicate and the bands shown represent typical
results. Type I collagen gene expression was suppressed and type II collagen gene expression increased on increasing the DHEA
concentration: *statistical significance in type I collagen expression (P<0.05), **statistical significance in type II collagen expression
(P<0.05).
Fig. 4. The effects of DHEA on the gene expressions of MMP-1, -3, and TIMP-1 as determined by RT-PCR. Chondrocytes in alginate beads
were treated with DHEA at 0, 10, 50, and 100 µM for 3 days. Experiments were performed in triplicate and the bands shown represent typical
results. The gene expression of MMP-1 was significantly reduced at DHEA concentrations of 50 and 100 µM. The gene expression of MMP-3
was also reduced, but no statistical significance was found. The gene expression of TIMP-1 was elevated at DHEA concentration of 10 µM:
*statistical significance in MMP-1 expression (P<0.05), **statistical significance in TIMP-1 expression (P<0.05).
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cartilage loss. The present study demonstrates that DHEA
treatment does not affect chondrocyte proliferation or GAG
synthesis up to 100 µM. However, the gene expressions
and syntheses of catabolic enzymes, such as MMP-1 and
-3, were significantly suppressed by DHEA, while those of
inhibitor of MMPs, such as TIMP-1, were significantly
stimulated. Furthermore, the effects of DHEA treatment
were accentuated by IL-1β treatment, as IL-1β-induced
gene expressions of MMP-1 and -3 were reduced at lower
concentration of DHEA.
In this work, DHEA treatment was not found to affect the
proliferation or viability of chondrocytes, regardless of the
DHEA concentration. We made use of the MTS method to
measure the activities of mitochondrial dehydrogenases of
viable cells. This method is known to produce results that
are similar to those obtained by the [3H]Thymidine uptake
assay32. In addition, by using this method, we were able to
measure the cytotoxicity of DHEA by directly measuring the
number of viable cells.
A few reports have been concerned with the proliferative
inhibitory effect of DHEA in other cell types and have
suggested that the inhibition might occur via a DHEA-
specific receptor that involves extracellular signal-regulated
kinase 1 (ERK1) signaling pathways33, via increasing
G0–G1 cell populations and simultaneously decreasing the
number of cells advancing to the S and G2–M cell cycle
Fig. 5. The effects of DHEA on the gene expressions of MMP-1 and -3 in the presence of IL-1β measured by RT-PCR. Chondrocytes in
alginate beads were treated with DHEA at 0, 10, 50 and 100 µM in the presence of 1000 pg/ml of IL-1β for 3 days. Experiments were
performed in triplicate and the bands shown represent typical results. DHEA treatment suppressed the gene expressions of MMP-1 and -3
more so in the presence of IL-1β: *statistical significance in MMP-1 expression (P<0.05), **statistical significance in MMP-3 expression
(P<0.05).
Fig. 6. The effects of DHEA on the protein syntheses of MMP-1, -3, and TIMP-1, as determined by Western blotting. Chondrocytes in alginate
beads were treated with DHEA at 0, 10, and 100 µM for 3 days. Experiments were performed in triplicate and the bands shown represent
typical results. The protein syntheses of MMP-1, -3, and TIMP-1 correlated with their gene expressions, indicating that DHEA acts at the
transcription level.
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phases34, or via inhibition of glucose-6-phosphate dehydro-
genase (G6PD)35. However, Yoneyama et al. reported
that the growth response to DHEA in vitro was markedly
affected by the culture conditions after experiments with
vascular smooth muscle cells from human or rat aorta36.
These divergent results reflect the current understanding
of the effects of DHEA on cell proliferation, which
demonstrably remains unclear.
The effects of DHEA on chondrocyte proliferation have
not been previously reported and are described for the first
time in the present study. On day 7 after culture for cell
proliferation assay using the MTS assay, the number of the
viable chondrocytes reached nearly 40 times that of day 1,
which means that the cells proliferated more than five-fold.
Also, cell proliferation was not affected by various concen-
trations used in the present study. This result indicates that
chondrocytes can proliferate actively in the presence of
DHEA, even at pharmacologic concentrations26 (>10 µM)
and that DHEA is not cytotoxic to chondrocytes.
In this in vitro study, DHEA was found to suppress the
gene expression of type I collagen and to simultaneously
increase the gene expression of type II collagen, both in a
dose-dependent manner. Normally, type I collagen is not
expressed in normal or osteoarthritic cartilage37. However,
chondrocytes cultured as monolayer undergo a gradual
dedifferentiation, characterized by a change from a spheri-
cal shape to a fibroblastic appearance. This occurs with
changes in the types of collagen synthesized from type II
into type I38,39. However, these changes have been re-
ported to be reversed when dedifferentiated chondrocytes
are transferred into alginate, i.e., type II collagen gene
expression is upregulated and type I collagen gene expres-
sion is downregulated40,41. In the present study, isolated
chondrocytes were cultured in monolayer for 7 days, which
resulted in some dedifferentiation of chondrocytes. After
transferring the monolayer-cultured chondrocytes to algi-
nate beads, they began to gradually re-express the
differentiated phenotype. DHEA accentuated the de-
creased gene expression of type I collagen and increased
the gene expression of type II collagen, which means
DHEA enhanced the re-expression of the chondrocyte
phenotype in the alginate beads.
Various MMPs, including MMP-1 and -3 are known to be
expressed in human42 or experimentally induced OA43–45,
though their expression patterns are contradictory46. The
activities of MMPs are regulated not only by gene expres-
sion, but also by the extracellular activation of proMMPs
and by the inhibition of endogenous TIMPs inhibitors. In
addition, cartilage destruction is believed to be caused by
an imbalance between activated MMPs and TIMPs47. The
expression of TIMPs has been thought to be relatively
constant, regardless of the progression of experimentally
induced OA48, treatment with hyaluronic acid49 or with
non-steroidal anti-inflammatory drugs (NSAIDs)50 or IL-
1β29. However, dexamethasone and IL-1β treatments were
found to reduce the expression of TIMPs51. We demon-
strated that treatment with DHEA significantly suppresses
the gene expression and protein synthesis of MMP-1,
which suggests that DHEA influences at the gene level
in the study. By contrast, DHEA increased the gene
expression and protein synthesis of TIMP-1, indicating that
DHEA has an anti-catabolic action, not only via MMPs
suppression, but also via TIMP-1 induction.
The effects of DHEA were more prominent in the
presence of IL-1β. DHEA suppressed the IL-1β-induced
expressions of MMP-1 and -3 at 10 and 50 µM, respect-
ively, which are lower concentrations when compared with
the results in the absence of IL-1β. As IL-1β is well known
to be elevated in osteoarthritic joints, these results indicate
that DHEA could significantly reduce cartilage destruction
in those joints via the suppression of the gene expressions
of MMP-1 and -3, and by increasing the gene expression of
TIMP-1, though we did not investigate the effect of DHEA
on the IL-1β-induced expression of TIMP-1. We did not
investigate the effect of DHEA on protein synthesis of
MMP-1, -3, and TIMP-1 in the presence of IL-1β. However,
because a study on the effect of DHEA on protein synthesis
should include investigations on the activity of those en-
zymes, and not only the protein levels, it seems to be
beyond the scope of this study, suggesting future studies.
The mechanisms of DHEA action in chondrocytes are not
clear. However, DHEA has been known to have anti-
inflammatory effects, both in cells other than chondrocytes
and/or in vivo via the inhibition of proinflammatory cytokine
secretion, such as TNF52,53, IL-154, and IL-655. Moreover,
the serum level of DHEA was found to be negatively
correlated with serum IL-6 in human56. The common mech-
anism of the anti-inflammatory action of DHEA seems to
concern the direct inhibition of nuclear factor kappa B
(NF-κB) transfer to the nucleus57 via the activation of
peroxisome proliferator activated receptor alpha (PPARα),
the inhibition of the binding of the nuclear factor activator
protein 1 (AP-1) to the DNA58, and peripheral conversion to
androgens and estrogens59. From this point of view, it is
interesting to note that the modulation of the gene expres-
sions of MMPs by IL-1 in chondrocytes is likely to be
mediated by serine–threonine kinases of the mitogen-
activated protein kinase (MAPK) family60, which comprises
ERK, the c-Jun N-terminal kinase (JNK), and p38. As the
endpoint of MAPK activation is the production of phospho-
rylated active AP-1 transcription factor, which is composed
of c-Jun and c-Fos, the effect of DHEA on the suppression
of MMPs, presumably, and at least in part, is likely to be
exerted via the inhibition of the MAPK kinase pathway. In
addition, as IL-1 increases the activity of NF-κB, a tran-
scription factor that regulates numerous proinflammatory
genes, such as MMP-1 and -361,62, the inhibitory effects of
DHEA may blockade the IL-1-induced activity of NF-κB.
Further studies are needed to elucidate the precise role of
DHEA in the production of chondrocyte MMPs.
This is the first study on the effects of DHEA on human
osteoarthritic chondrocytes. Our results demonstrate that
DHEA does not exert significant influence on cell prolifer-
ation or viability, or GAG production. On the other hand,
DHEA does suppress the gene expressions and protein
syntheses of MMP-1 and -3 and increase those of TIMP-1.
Furthermore, the inhibitory effects of DHEA on the
gene expressions of MMP-1 and -3 were found to be
accentuated in the presence of IL-1β.
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